What We Do

Helping Patients in Need of New Treatment Options

Salarius Pharmaceuticals is a cancer-focused biopharmaceutical company using targeted protein inhibition and targeted protein degradation to develop new therapies to address gene dysregulation, with potential to work in both liquid and solid tumors. Our lead protein inhibitor, seclidemstat (SP-2577), represents a potential paradigm shift in the treatment of cancer. We are targeting Ewing sarcoma, a devastating bone cancer affecting pediatric, adolescent, and young adult patients, for which no targeted therapies are currently available. We are collaborating with the MD Anderson Cancer Center to target hematologic or blood cancers.

SP-3164 is our lead targeted protein degrader. It is a differentiated molecular glue that promotes selective degradation of the transcription factors Ikaros and Aiolos and has the potential to treat hematological cancers and solid tumors. SP-3164 is expected to enter the clinic in the second half of 2023.

Produced by MendozaMedia.net

Leadership Team

Board of Directors